JP6691477B2 - クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法 - Google Patents

クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法 Download PDF

Info

Publication number
JP6691477B2
JP6691477B2 JP2016519675A JP2016519675A JP6691477B2 JP 6691477 B2 JP6691477 B2 JP 6691477B2 JP 2016519675 A JP2016519675 A JP 2016519675A JP 2016519675 A JP2016519675 A JP 2016519675A JP 6691477 B2 JP6691477 B2 JP 6691477B2
Authority
JP
Japan
Prior art keywords
days
composition
toxin
difficile
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016519675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521754A (ja
JP2016521754A5 (enExample
Inventor
ピエトロボン，パトリシア
フォーリア，ジーナマリー
ブリュイン，ガイ デ
ブリュイン，ガイ デ
グルナサン，サンジャイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Sanofi Pasteur Inc
Original Assignee
Aventis Pasteur SA
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51168412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6691477(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur SA, Sanofi Pasteur Inc filed Critical Aventis Pasteur SA
Publication of JP2016521754A publication Critical patent/JP2016521754A/ja
Publication of JP2016521754A5 publication Critical patent/JP2016521754A5/ja
Application granted granted Critical
Publication of JP6691477B2 publication Critical patent/JP6691477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016519675A 2013-06-14 2014-06-13 クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法 Active JP6691477B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
US61/835,246 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (3)

Publication Number Publication Date
JP2016521754A JP2016521754A (ja) 2016-07-25
JP2016521754A5 JP2016521754A5 (enExample) 2017-07-27
JP6691477B2 true JP6691477B2 (ja) 2020-04-28

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519675A Active JP6691477B2 (ja) 2013-06-14 2014-06-13 クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法

Country Status (12)

Country Link
US (4) US9730994B2 (enExample)
EP (1) EP3007724B1 (enExample)
JP (1) JP6691477B2 (enExample)
KR (1) KR20160020543A (enExample)
CN (1) CN105611942A (enExample)
AU (1) AU2014277981B2 (enExample)
BR (1) BR112015031088A2 (enExample)
CA (1) CA2915279A1 (enExample)
MX (1) MX2015017257A (enExample)
SG (1) SG11201510166YA (enExample)
TW (1) TWI648063B (enExample)
WO (1) WO2014201346A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5917682B2 (ja) 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US9730994B2 (en) 2013-06-14 2017-08-15 Sanofi Pasteur, Inc. Compositions and methods for immunizing against C. difficile
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2020003756A (es) * 2017-09-28 2020-07-29 Pfizer Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
CN106039299A (zh) 2007-09-14 2016-10-26 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
JP5917682B2 (ja) 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
WO2014144567A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
SG11201507578PA (en) * 2013-03-15 2015-10-29 Sanofi Pasteur Inc Toxoid, compositions and related methods
US9730994B2 (en) 2013-06-14 2017-08-15 Sanofi Pasteur, Inc. Compositions and methods for immunizing against C. difficile

Also Published As

Publication number Publication date
CN105611942A (zh) 2016-05-25
EP3007724A1 (en) 2016-04-20
TW201536314A (zh) 2015-10-01
WO2014201346A1 (en) 2014-12-18
BR112015031088A2 (pt) 2017-07-25
US20210145956A1 (en) 2021-05-20
TWI648063B (zh) 2019-01-21
MX2015017257A (es) 2016-11-11
JP2016521754A (ja) 2016-07-25
EP3007724B1 (en) 2023-07-05
US20160120968A1 (en) 2016-05-05
CA2915279A1 (en) 2014-12-18
AU2014277981B2 (en) 2019-06-20
AU2014277981A1 (en) 2016-01-07
SG11201510166YA (en) 2016-01-28
KR20160020543A (ko) 2016-02-23
US11419930B2 (en) 2022-08-23
US20200113991A1 (en) 2020-04-16
US9730994B2 (en) 2017-08-15
US20170304423A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
US11419930B2 (en) Compositions and methods for immunizing against C. difficile
De Bernardis et al. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models
US11680087B2 (en) Neisseria meningitidis compositions and methods thereof
US20210085773A1 (en) Neisseria meningitidis compositions and methods thereof
US20250312432A1 (en) Compositions and methods for eliciting an immune response against clostridium difficile
RU2559782C2 (ru) Набор для детекции спор, происходящих из микобактерий
Ribeiro et al. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice
WO2018006939A1 (en) Inactivated tuberculosis vaccine
JP2021503509A (ja) 哺乳動物における趾皮膚炎に使用されるワクチン組成物
US20220313816A1 (en) Compositions and methods for antibody-as-adjuvant vaccines and therapeutics
Sanders Investigation of the potential of PorA and FetA as meningococcal vaccine components

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200410

R150 Certificate of patent or registration of utility model

Ref document number: 6691477

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250